Latest Disclosure Compliance News

Lycopodium Limited has addressed ASX concerns over delayed director interest disclosures, attributing the lapse to an administrative oversight while reaffirming its compliance policies.

Cauldron Energy Limited addresses a sharp share price rise, attributing it to strong uranium exploration results and market speculation linked to a sector takeover.

Resolution Minerals has clarified its compliance with ASX disclosure rules following a $2 million placement to Tribeca Investment Partners, confirming the transaction's material impact on its share price.

Sagalio Energy’s shares surged sharply on November 12, prompting ASX to demand clarity on undisclosed information and compliance with disclosure rules.

ALS Limited has responded to an ASX inquiry regarding the delayed lodgement of key disclosure documents related to performance rights granted to director Malcolm Deane, attributing the delay to human error and outlining steps to reinforce compliance.

Aguia Resources has responded to an ASX price query following a dramatic surge in its share price, confirming no new material exploration results have been received or withheld. The company asserts full compliance with continuous disclosure obligations despite market speculation.

Worley Limited has affirmed its FY25 earnings were consistent with prior guidance and analyst expectations, with only a minor margin outperformance deemed immaterial. The company confirms compliance with ASX continuous disclosure rules following an ASX inquiry.

Ramsay Health Care has clarified that its underlying earnings for FY25 aligned closely with market consensus, despite a significant non-cash impairment impacting statutory profits. The company confirms compliance with ASX disclosure rules amid share price volatility.

RPMGlobal Holdings clarifies the reasons behind withdrawing its FY2025 earnings guidance following the divestment of its Advisory business, providing detailed updates on software segment performance and compliance with ASX disclosure rules.

EVT Limited has responded to ASX inquiries confirming its FY25 earnings were broadly in line with market forecasts, despite a notable post-results share price decline.

AGL Energy has clarified that its FY25 underlying earnings aligned with market forecasts and published guidance, dismissing any material surprises in its financial results. The company also addressed statutory profit volatility and confirmed compliance with ASX disclosure rules.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.